Pyrrolocarbazoles as Checkpoint 1 Kinase Inhibitors

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Pyrrolocarbazoles as Checkpoint 1 Kinase Inhibitors

Anti-Cancer Agents in Medicinal Chemistry, 8(6): 577-597.

Author(s): Helene Henon, Elisabeth Conchon, Bernadette Hugon, Samir Messaoudi, Roy M. Golsteyn and Michelle Prudhomme.

Affiliation: Laboratoire SEESIB, Universite Blaise Pascal, UMR 6504 du CNRS, 24 Avenue des Landais, 63177 Aubiere, France.


The carbazole framework is found in many natural compounds of biological interest. Indolocarbazoles such as rebeccamycin and staurosporine which are either a topoisomerase I inhibitor (rebeccamycin) or a non selective kinase inhibitor (staurosporine) are bacterial metabolites. In the search for new antitumor agents, DNA damage checkpoint kinases, in particular Checkpoint kinase 1, have recently emerged as attractive targets for cancer therapy. This review reports the synthesis and Chk1 inhibitory activities of pyrrolocarbazole compounds bearing four or five fused rings.


Checkpoint kinase 1, antitumor agents, pyrrolocarbazole, granulatimide.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 8
Issue Number: 6
First Page: 577
Last Page: 597
Page Count: 21
DOI: 10.2174/187152008785133100
Price: $58
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals

Related eBooks

Webmaster Contact: Copyright © 2017 Bentham Science